Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KITE
  • CUSIP:
Key Metrics:
  • Previous Close: $58.04
  • 50 Day Moving Average: $55.50
  • 200 Day Moving Average: $50.35
  • 52-Week Range: $38.41 - $89.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.75
  • P/E Growth: 0.00
  • Market Cap: $2.88B
  • Outstanding Shares: 49,596,000
  • Beta: 2.48
Additional Links:
Companies Related to Kite Pharma:

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 1 Hold Rating, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.93)
Consensus Price Target: $76.00 (30.94% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
DateFirmActionRatingPrice TargetDetails
8/9/2016MizuhoSet Price TargetBuy$80.00View Rating Details
8/9/2016Barclays PLCSet Price TargetHold$58.00 -> $60.00View Rating Details
8/9/2016Maxim GroupReiterated RatingBuy$87.00 -> $77.00View Rating Details
8/5/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/26/2016Canaccord GenuityReiterated RatingBuy$75.00View Rating Details
7/13/2016Stifel NicolausBoost Price TargetHold -> Buy$63.00 -> $74.00View Rating Details
7/10/2016FBR & CoReiterated RatingOutperform$75.00View Rating Details
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/2/2016Raymond James Financial Inc.Initiated CoverageOutperform$61.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
3/20/2016SunTrust Banks Inc.Reiterated RatingBuy$70.00View Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$111.00 -> $92.00View Rating Details
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details
8/14/2015GuggenheimReiterated RatingBuyView Rating Details
5/5/2015Credit Suisse Group AGReiterated RatingOutperform$79.00View Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.60)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.54)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.38)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.40)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$0.12($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.20)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kite Pharma (NASDAQ:KITE)
Current Year EPS Consensus Estimate: $-5.92 EPS
Next Year EPS Consensus Estimate: $-6.63 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.37)($0.93)($1.09)
Q2 20163($1.30)($1.15)($1.24)
Q3 20163($1.74)($1.66)($1.70)
Q4 20163($2.18)($2.05)($2.11)
(Data provided by Zacks Investment Research)


Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Kite Pharma (NASDAQ:KITE)
News IconHC Stocks to watch for: Kite Pharma Inc (KITE), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - share market updates (press release) (NASDAQ:KITE) - August 30 at 9:05 AM logoInteresting KITE Put And Call Options For April 2017 (NASDAQ:KITE) - August 23 at 10:16 AM
News IconStock Trading Above Moving Averages: Kite Pharma, Inc. (NASDAQ:KITE) - Post News (NASDAQ:KITE) - August 22 at 5:54 PM
News IconTime To Put On The Watch List? - Kite Pharma, Inc. (NASDAQ:KITE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - The Voice Registrar (NASDAQ:KITE) - August 20 at 9:59 AM logoKite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy ... - Business Wire (press release) (NASDAQ:KITE) - August 19 at 8:52 AM logoKite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award (NASDAQ:KITE) - August 19 at 8:52 AM logoForm 4 Kite Pharma, Inc. For: May 19 Filed by: Kim Helen Susan - (NASDAQ:KITE) - August 18 at 5:53 PM logoKITE PHARMA, INC. Financials (NASDAQ:KITE) - August 17 at 6:03 PM logoForm 4 Kite Pharma, Inc. For: May 19 Filed by: Kim Helen Susan (NASDAQ:KITE) - August 17 at 8:54 AM logoKite Pharma Inc. (KITE) Has Risen To Over A 7-Month High (NASDAQ:KITE) - August 15 at 6:03 PM logoKite Pharma : to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:KITE) - August 11 at 6:06 PM logoETF’s with exposure to Kite Pharma, Inc. : August 11, 2016 (NASDAQ:KITE) - August 11 at 6:06 PM logoKite Pharma's Stock Upside Seen Slipping to $77 - Barron's (NASDAQ:KITE) - August 11 at 8:56 AM logoKite Pharma, Inc. :KITE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:KITE) - August 10 at 6:08 PM logoKite Pharma : reports 2Q loss (NASDAQ:KITE) - August 8 at 6:03 PM
News IconKite Pharma Reports Second Quarter 2016 Financial Results (NASDAQ:KITE) - August 8 at 6:03 PM logoKite Pharma reports 2Q loss (NASDAQ:KITE) - August 8 at 6:03 PM logoCurrent Analysts Rating Update: Quintiles Transitional Holdings Inc. (NYSE:Q) , Kite Pharma, Inc. (NASDAQ:KITE) - Street Updates (NASDAQ:KITE) - August 8 at 10:32 AM logoQ2 2016 Kite Pharma Inc Earnings Release - After Market Close (NASDAQ:KITE) - August 8 at 10:32 AM logoRhenman Partners Asset Management Ab adds Kite Pharma Inc (KITE) to its portfolio - Trade Calls (NASDAQ:KITE) - August 7 at 5:34 PM
News IconIt's Earnings Time: What to Do with Kite Pharma, Inc. (NASDAQ:KITE) Stock - The Voice Registrar (NASDAQ:KITE) - August 5 at 5:58 PM logoInvestors Trading Alert: Molina Healthcare Inc (NYSE:MOH) , Kite Pharma, Inc. (NASDAQ:KITE) - Street Updates (NASDAQ:KITE) - August 5 at 5:58 PM logo5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More (NASDAQ:KITE) - August 5 at 8:51 AM logoWhy Kite Pharma, Inc. Surged 11.1% Higher in July (NASDAQ:KITE) - August 5 at 8:51 AM logoNotable Analyst's Ranking Preview: Kite Pharma, Inc. (NASDAQ:KITE) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates (NASDAQ:KITE) - August 4 at 6:07 PM
News IconAmgen buying rights to Advaxis cancer treatment (NASDAQ:KITE) - August 3 at 6:10 PM logoKite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:KITE) - August 3 at 6:09 PM logoKite Pharma to Report Second Quarter 2016 Financial Results on ... - Business Wire (press release) (NASDAQ:KITE) - August 1 at 5:42 PM logoKite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016 (NASDAQ:KITE) - August 1 at 5:42 PM logoKite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 … (NASDAQ:KITE) - July 29 at 8:47 AM logoBRIEF-Kite Pharma announces license with NIH for anti-CD19 chimeric antigen receptor - Reuters (NASDAQ:KITE) - July 28 at 8:54 AM logoKite Pharma Announces Exclusive License with the National ... - Business Wire (press release) (NASDAQ:KITE) - July 27 at 6:07 PM logoKite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies (NASDAQ:KITE) - July 27 at 4:28 PM logo4:07 pm Kite Pharma enters into an exclusive, worldwide license with the NIH for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies (NASDAQ:KITE) - July 27 at 4:07 PM logoCompany Update (NASDAQ:KITE): Kite Pharma Inc Licenses Enabling Technology for the Development of Off-the ... - Smarter Analyst (NASDAQ:KITE) - July 26 at 6:04 PM logoKite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies (NASDAQ:KITE) - July 25 at 4:38 PM logo[$$] Bloodlines: Rivals look to create 'off-the-shelf' treatment (NASDAQ:KITE) - July 24 at 1:54 PM
News IconKite Pharma, Inc. (NASDAQ:KITE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:KITE) - July 23 at 9:50 AM logoKite Pharma, Inc. breached its 50 day moving average in a Bullish Manner : KITE-US : July 22, 2016 (NASDAQ:KITE) - July 22 at 8:08 AM
News IconKite Pharma Incorporated (NASDAQ:KITE) Short Interest Increased By 3.17% - Consumer Eagle (NASDAQ:KITE) - July 21 at 6:00 PM logoKite Pharma (NASDAQ:KITE) soared 5.17%: Marvell Technology Group Ltd. (NASDAQ:MRVL), The Walt Disney ... - KC Register (NASDAQ:KITE) - July 21 at 6:00 PM
News IconEquity Roundup: Stock Performance Focus on Kite Pharma, Inc. (NASDAQ:KITE) - Press Telegraph (NASDAQ:KITE) - July 21 at 6:00 PM
News IconStock Focus: Following Analyst Expectations on Shares of Kite Pharma, Inc. (NASDAQ:KITE) - TGP (NASDAQ:KITE) - July 20 at 3:57 PM
News IconOXIS International, Inc. (OTCMKTS:OXIS) & Kite Pharma Inc (NASDAQ:KITE) Provide Safe Haven for Investors for ... - Journal Transcript (NASDAQ:KITE) - July 20 at 3:57 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Kite Pharma, Inc. (NASDAQ:KITE) - TGP (NASDAQ:KITE) - July 20 at 3:57 PM
News IconSolid Performer in Focus: Kite Pharma, Inc. (NASDAQ:KITE) - Engelwood Daily (NASDAQ:KITE) - July 20 at 3:57 PM logoKite Pharma, Inc. – Value Analysis (NASDAQ:KITE) : July 18, 2016 (NASDAQ:KITE) - July 18 at 3:55 PM
News IconHow Many Kite Pharma Inc (NASDAQ:KITE)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:KITE) - July 18 at 11:06 AM
News IconKite Pharma, Inc. (NASDAQ:KITE) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:KITE) - July 17 at 10:11 AM logoKite Pharma Inc Realized Volatility Hits a Dropping Level - CML News (NASDAQ:KITE) - July 16 at 9:13 AM


Kite Pharma (NASDAQ:KITE) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff